Top Page
Pro Medicus Limited
(Sydney:PME)
Pro Medicus Limited (PME) vs. iShares MSCI Australia ETF (EWA)
Pro Medicus Limited Business Overview & Revenue Model
Pro Medicus Limited Earnings Call Summary
Pro Medicus Limited Financial Statement Overview
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 184.58M | 161.43M | 124.90M | 93.46M | 67.88M | 56.82M |
| Gross Profit | 144.39M | 122.24M | 92.36M | 92.94M | 46.66M | 56.42M |
| EBITDA | 146.87M | 120.69M | 91.69M | 69.64M | 49.53M | 37.70M |
| Net Income | 98.29M | 82.79M | 60.65M | 44.44M | 30.85M | 23.08M |
Balance Sheet | ||||||
| Total Assets | 294.18M | 257.43M | 202.13M | 157.05M | 125.57M | 95.64M |
| Cash, Cash Equivalents and Short-Term Investments | 182.33M | 154.89M | 121.50M | 90.55M | 61.82M | 43.41M |
| Total Debt | 1.83M | 2.07M | 1.85M | 2.28M | 2.62M | 2.28M |
| Total Liabilities | 71.93M | 69.70M | 63.36M | 55.32M | 43.89M | 35.46M |
| Stockholders Equity | 222.25M | 187.73M | 138.78M | 101.73M | 81.68M | 60.18M |
Cash Flow | ||||||
| Free Cash Flow | 104.47M | 80.08M | 58.33M | 53.20M | 31.33M | 23.72M |
| Operating Cash Flow | 107.89M | 86.78M | 64.77M | 62.23M | 39.02M | 31.59M |
| Investing Cash Flow | -80.26M | -78.07M | -9.79M | -17.56M | -27.40M | -7.87M |
| Financing Cash Flow | -45.04M | -39.84M | -27.53M | -23.31M | -14.05M | -12.31M |
Pro Medicus Limited Technical Analysis
Pro Medicus Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | $28.94B | 294.41 | 52.66% | 0.18% | 29.87% | 40.97% | |
51 Neutral | $7.41B | 0.32 | -61.11% | 2.34% | 16.99% | 1.69% | |
| $54.57M | ― | -9.88% | ― | ― | ― | ||
62 Neutral | AU$17.01M | 140.00 | -3.11% | ― | 89.13% | 69.57% | |
55 Neutral | AU$141.01M | ― | -5.63% | ― | -11.96% | 7.50% | |
55 Neutral | AU$62.63M | ― | -457.46% | ― | 21.93% | 10.34% | |
53 Neutral | AU$48.73M | 110.00 | -8.34% | ― | -5.27% | 50.29% |
Pro Medicus Limited Corporate Events
Pro Medicus Limited has secured a AUD $20 million, 5-year contract with University of Iowa Health Care to implement its Visage 7 Enterprise Imaging Platform across the institution. This agreement will replace the legacy PACS system with a cloud-based solution, enhancing diagnostic imaging and integrating with electronic health records. The rollout is set to begin immediately, with completion targeted for Q4 2025, marking a significant step in Pro Medicus’s expansion in the healthcare IT sector.
Pro Medicus Limited announced a multi-year research collaboration agreement with UCSF to leverage the Visage AI Accelerator platform for AI research and development aimed at product commercialization. This collaboration aligns with Pro Medicus’s strategy to integrate AI into healthcare imaging, potentially leading to innovative solutions that improve patient outcomes and strengthen the company’s position in the imaging IT industry.
Pro Medicus Limited has announced the cessation of 2,610 ordinary fully paid securities through an on-market buy-back, effective April 4, 2025. This move is part of the company’s capital management strategy and may impact its share structure, potentially enhancing shareholder value and optimizing its financial operations.
Pro Medicus Limited has announced an update regarding its ongoing on-market buy-back program. As of April 7, 2025, the company has repurchased a total of 7,648 ordinary fully paid securities, including 2,610 bought back on the previous day. This buy-back initiative is part of Pro Medicus’s strategy to manage its capital structure and potentially enhance shareholder value.
Pro Medicus Limited announced the cessation of 2,518 ordinary fully paid securities following an on-market buy-back, effective April 2, 2025. This move is part of the company’s capital management strategy, potentially impacting its share structure and market perception positively by demonstrating financial strength and shareholder value commitment.
Pro Medicus Limited has announced an update on its ongoing on-market buy-back program, revealing the acquisition of 2,518 ordinary fully paid securities on the previous day, adding to a total of 2,520 securities bought back prior. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value, reflecting a proactive approach in maintaining its market positioning.
Pro Medicus Limited announced the cessation of 2,520 ordinary fully paid securities as part of an on-market buy-back, effective April 1, 2025. This move is part of the company’s capital management strategy, potentially impacting its stock liquidity and shareholder value positively by reducing the number of shares outstanding.
Pro Medicus Limited has announced a daily buy-back of its ordinary fully paid securities, with 2,520 shares bought back on the previous day. This move is part of an ongoing strategy to manage the company’s capital structure, potentially enhancing shareholder value and signaling confidence in the company’s financial health.
Pro Medicus Limited has announced an on-market buy-back of its ordinary fully paid shares, indicating a strategic move to optimize its capital structure and potentially enhance shareholder value. This buy-back may reflect the company’s confidence in its financial health and future prospects, and could positively influence its market positioning and stakeholder interests.
Pro Medicus Limited has announced an update regarding its ongoing on-market buy-back program. The company has repurchased a total of 27,076 ordinary fully paid securities before the previous day and an additional 1,250 securities on the previous day. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value.
Pro Medicus Limited announced the cessation of 1,220 ordinary fully paid securities due to an on-market buy-back, effective March 28, 2025. This move is part of the company’s capital management strategy, potentially impacting its financial structure and shareholder value by reducing the number of outstanding shares.
Pro Medicus Limited has announced a daily update on its ongoing on-market buy-back program. As of March 31, 2025, the company has repurchased a total of 25,856 ordinary fully paid securities, with an additional 1,220 securities bought back on the previous day. This buy-back initiative reflects Pro Medicus Limited’s strategic approach to managing its capital structure and potentially enhancing shareholder value.